Metformin / Biguanide

Metformin is a biguanide compound that has been the first-line treatment for type 2 diabetes (T2D) for decades. FDA-approved in 1994, it is generic, inexpensive, and among the most extensively studied compounds in clinical pharmacology. Its safety profile over 60+ years of use is unmatched by nearly any other metabolic pharmaceutical.

What began as a diabetes management tool has evolved into a subject of intense longevity and aging research. Investigators like David Sinclair (Harvard) and Nir Barzilai (Albert Einstein College of Medicine) have explored Metformin's potential as a caloric restriction mimetic — a compound that replicates some of the cellular signaling patterns seen in fasting and caloric restriction without the behavioral demands.

Barzilai is leading the landmark TAME trial (Targeting Aging with Metformin) — a $75 million NIH-backed clinical trial designed specifically to test whether Metformin can delay the onset of age-related diseases and extend healthspan in non-diabetic adults. This is the first trial designed to treat "aging" as an indication, potentially opening regulatory pathways for longevity compounds.

In biohacking and performance research communities, Metformin is increasingly studied for its effects on insulin sensitivity, AMPK pathway activation, and interactions with anabolic signaling — including a recognized tension between its mTOR-suppressing longevity benefits and potential interference with muscle protein synthesis in resistance-training research subjects.

Metformin has a multi-pathway mechanism that distinguishes it from most antidiabetics and explains its appeal in longevity research:

Longevity mechanism in brief: mTOR inhibition reduces anabolic signaling and promotes autophagy — the cellular "recycling" process. Multiple animal models (C. elegans, mice) have shown lifespan extension with Metformin. Whether this translates to humans is what the TAME trial is designed to determine.

Metformin is the most prescribed antidiabetic medication worldwide and among the most extensively studied drugs in clinical medicine. The UK Prospective Diabetes Study (UKPDS 34, 1998) established metformin as first-line therapy for overweight T2D patients, demonstrating a 36% reduction in all-cause mortality. The Diabetes Prevention Program (DPP, Knowler et al. 2002) showed 850 mg twice daily reduced T2D incidence by 31% in high-risk adults. Current longevity research, including the TAME (Targeting Aging with Metformin) trial led by Barzilai, investigates metformin's potential to delay age-related disease onset.

Titration: Always start at the lowest effective dose and titrate slowly to reduce GI side effects. The extended-release (XR) formulation substantially reduces nausea and diarrhea and is the preferred format for research subjects sensitive to GI effects.

Timing: Take with food — always. This is critical for GI tolerability and absorption optimization. Evening meal dosing is preferred in longevity protocols to time AMPK activation during the overnight fasting window.

Contraindications for use: Renal impairment (eGFR below 30 mL/min/1.73m²) — significantly elevated lactic acidosis risk. Hold 12–24 hours before iodinated contrast (CT/MRI with contrast) and restart no sooner than 48 hours after, once renal function is confirmed stable.

Monitoring is critical for safe Metformin research protocols. Key panels:

Metabolic / Glycemic Panel

Renal Function — Must be normal before initiating; re-check at least annually

Vitamin B12 — Annually for long-term users. Metformin reduces B12 absorption via terminal ileum interference — deficiency documented in 10–30% of long-term users. Deficiency can cause macrocytic anemia and peripheral neuropathy.

Safety Markers

• Common
  GI Effects — Nausea, diarrhea, abdominal discomfort, bloating. Present in 20–30% of subjects. Typically improve with time or dose reduction. Substantially reduced with XR formulation or taking with food.
• Common
  Metallic Taste — Reported commonly in early use, tends to diminish over time.
• Chronic
  Vitamin B12 Deficiency — Documented in 10–30% of long-term users via reduced ileal absorption. Can lead to macrocytic anemia and peripheral neuropathy if unmonitored. Supplement with methylcobalamin.
• Rare
  Lactic Acidosis — Rare but life-threatening. Incidence approximately 1–5 cases per 100,000 patient-years. Primarily a risk in subjects with renal impairment, liver disease, contrast media exposure, sepsis, or hypoxia. Metformin is contraindicated in eGFR <30.
• Note
  No Hypoglycemia Risk as Monotherapy — Metformin does not stimulate insulin secretion. Hypoglycemia does not occur with Metformin alone (only when combined with insulin secretagogues).
• Research Context
  Exercise Adaptation Interference — The MASTERS trial (Konopka et al., Nature Aging 2019) found that Metformin may blunt exercise-induced mitochondrial biogenesis in older adults. This is an active area of debate — the longevity vs. performance tension is real and relevant for research protocol design.

GI Tolerability Protocol: Always take with food. Start at 500mg once daily for 1–2 weeks before increasing. If GI effects are significant, switch to XR formulation. The XR form dramatically reduces GI side effects by slowing absorption and reducing peak intestinal Metformin concentration.

Contrast Procedure Protocol: Alert treating physicians and radiologists to Metformin use before any imaging procedure requiring iodinated contrast. Hold 12–24 hours before, restart 48 hours after renal function confirmation.

Avoid in Liver Disease: Hepatic impairment increases lactic acidosis risk by impairing lactate clearance. Elevated LFTs at baseline warrant careful evaluation before proceeding with Metformin protocols.

• TAME Trial — Targeting Aging with Metformin
  Barzilai et al. / AFAR (American Federation for Aging Research). Ongoing $75M NIH-backed RCT. First trial designed to test whether a compound can delay aging as a primary endpoint — not a disease. Non-diabetic adults aged 65–79. Primary endpoint: composite of cardiovascular events, cancer, dementia, disability, and death.
• UKPDS — United Kingdom Prospective Diabetes Study
  30+ year landmark trial. Demonstrated Metformin's cardiovascular mortality benefit in T2D independent of glycemic control — the first suggestion that Metformin has effects beyond glucose lowering. Foundation for Metformin's position as first-line T2D therapy.
• MASTERS Trial — Metformin and Exercise Adaptation
  Konopka et al., Nature Aging (2019). Found that Metformin blunts exercise-induced improvements in insulin sensitivity and mitochondrial biogenesis in older adults undergoing resistance training. Key trial for the longevity vs. performance research debate.
• Cabreiro et al. — Metformin and Lifespan Extension
  Cell (2013). Demonstrated Metformin extends lifespan in C. elegans via AMPK-dependent mechanisms and gut microbiome modulation. Foundational preclinical evidence for longevity research application.
• Bannister et al. — Metformin Survival Benefit
  Diabetes, Obesity and Metabolism (2014). Observational data showing T2D patients on Metformin had longer survival than matched non-diabetic controls not on Metformin — a provocative finding that helped launch the formal longevity hypothesis.
• Lalau et al. — Lactic Acidosis Risk Stratification
  Series of publications defining the true incidence of Metformin-associated lactic acidosis (MALA) and demonstrating that risk is primarily driven by pre-existing contraindications (renal failure, liver disease, hypoxia) rather than Metformin itself at therapeutic doses.